THE INFORMATION CONTAINED WITHIN THIS
ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE
INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU)
NO. 596/2014, AS AMENDED ("MAR"). ON THE PUBLICATION OF THIS
ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE
("RIS"), THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE
PUBLIC DOMAIN.
DiscovOre plc
AQSE: ORE
(“DiscovOre plc” or the “Company”)
DiscovOre plc
Investee Update: Angelfish Investments plc, ARCADIA Trial
Update
Particulars of the RIS
Announcement:
1. Investee: Angelfish Investments
plc
2. Investee: Angelfish Investments
Update
3. Related Party Disclosure
1. Investee:
Angelfish Investments plc (“To be renamed 1graine plc”)
On the 28th of June
2021, all resolutions were passed at a General Meeting
convened by Angelfish Investments plc. Following the passing of the
resolutions, Angelfish Investments plc raised gross proceeds of,
£2,000,500, adopted a new investment strategy and amongst other
proposals completed a co-investment rights agreement with Excalibur
Healthcare Services. A company founded by globally renowned life
sciences & biotech entrepreneur, Sir Professor Christopher
Evans OBE whom in conjunction with the transaction, joined the
Board of Angelfish Investments plc as Executive Chairman.
DiscovOre plc subscribed for, 21,312,460 shares which on
admission represents 24.64% of the issued share capital.
2. Angelfish
Investments plc (“to be named 1graine plc”) Update:
Angelfish Investments plc announces, “Excalibur Medicines
reports completion of the Arcadia Trial & starts to progress
commercial plans”
as released by, Angelfish Investments plc -
https://www.investegate.co.uk/angelfish-inv.-plc--angp-/rns/arcadia-trial-update/202107091030017576E/
Particulars of the RIS:
1. Background: Excalibur Medicines Ltd
(“EML”)
2. EML: Corporate Update
3. Directors Statement
1. Background: EML Investee
Following the General Meeting held on the 28th
June 2021, Angelfish Investments plc
proceeded to secure a 2% Equity Interest in, Excalibur Medicines
Ltd (“EML”), consistent with the terms of the co-investment
agreement entered with Excalibur Healthcare Services, a company
founded by renowned biotech entrepreneur and the company’s newly
appointed Executive Chairman, Sir Professor Christopher Evans.
Excalibur Medicines Ltd (“EML”) has secured exclusive rights to
and owns the patents on a drug, AZD1656, which is being developed
as a potential therapeutic for people with diabetes suffering from
COVID-19. As there are very few new therapeutics in development for
COVID-19 and associated virally transmitted diseases (most research
is in combining existing treatments) this has the potential to be
highly attractive to big pharma and biotech buyers.
Angelfish Investments plc notes the announcement on July 8, 2021 by EML giving an update on the
advanced clinical trial of AZD1656.
www.excaliburhealth.co.uk/news
2. EML: Corporate Update
The Company is delighted to announce that the ARCADIA trial has
now completed several major milestones. It completed all
patient enrolment and dosing in April, has successfully completed
the process of data collection and collation from the 31 sites
involved in the trial and as of 2nd July has locked the
database for full analysis. The formal report with the results of
the trial is expected in late August.
The research project was arranged and structured by Professor
Sir Chris Evans, Chairman and CEO of
Excalibur Healthcare Services, through its subsidiary, Excalibur
Medicines Ltd. Sir Chris worked closely with Professor John Martin and his team at St George Street, a
UK-based biomedical research charity, which secured the initial
project and permission to run the trial from AstraZeneca.
At this time, St George Street (“SGS”) and EML have begun the
process of progressing commercialisation plans, subject to the
trial data being successful. Analysis is based broadly on a
combination of the anticipated mechanism of the drug and the
relevant data from the trial endpoints – reduction in mortality,
slowing in disease progression, glycaemic and inflammatory
reduction.
Another area investigated during the trial which could be
attractive if the data proves compelling is the possible
up-regulation of T-reg cell activity which it is thought would
promote long term immunity, beyond the normal life of a
vaccine.
Director Statement
Martin Walton, Executive Director
of Angelfish, said: “It is with great pleasure that following
the company’s investment only last week we are providing a
corporate update confirming the completion of the ARCADIA trial and
outlining the next practical steps involved as we eagerly await the
final report on the results of the trial which we expect to receive
in August.
The completion of the trial now
enables commercial discussions to be progressed in anticipation of
the final report, which is a critical focus in realising the
potential value of the work to date.
“During the trial, EML investigated
the possible up-regulation of T-reg cell activity which subject to
the data, is thought to promote long term immunity beyond the
normal life of a vaccine which is something of much discussion at
present and could itself prove to be valuable.”
3. Related Party Disclosure
Burns Singh Tennent-Bhohi is a Director of Angelfish Investments
plc, constituting related party disclosure under rule 4.6 of the
AQSE Growth Market Exchange Rulebook
DiscovOre plc,
London, 12th
July 2021
The Directors of the Company, who have issued this RIS
announcement after due and careful enquiry, accept responsibility
for its content.
Enquiries
Company:
Burns Singh Tennent-Bhohi (Director)
Conrad Windham (Director)
info@discovoreplc.com
Direct Office Line: +44 (0) 20 3778 0755
Corporate Adviser:
Peterhouse Capital Limited
Guy Miller & Mark Anwyl
Telephone: +44 (0) 20 7220 9796